Phase 2
Completed N=67
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Source: ClinicalTrials.gov NCT00551213 ↗Enrolled (actual)
67
Serious AEs
31.3%
Results posted
Dec 2015
Primary outcomePrimary: Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion — 7 Participants
Summary
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
The primary study hypothesis was that decreases in Positron Emission Tomography (PET)-assessed tumor glucose metabolism (i.e., fluorodeoxyglucose [FDG] standardized uptake value [SUV]) following administration of 10 mg/kg robatumumab will exceed those following administration of 0.3 mg/kg robatumumab in participants with relapsed or recurrent colorectal cancer who had progressed after first-line chemotherapy.
Investigator choices of standard chemotherapy: irinotecan as a single agent +/- cetuximab OR capecitabine as a single agent, OR FOLFOX (leucovorin calcium [folinic acid][FOL] + fluorouracil [F] + oxaliplatin [OX]) OR CAPEO(capecitabine [CAPE] or Xeloda® [XEL] + oxaliplatin [OX]) OR FOLFIRI (leucovorin calcium [folinic acid][FOL] + fluorouracil [F] + irinotecan [IRI]) +/- cetuximab OR cetuximab as a single agent.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion |
7 | — |
| SECONDARY Number of Participants Who Experienced One or More Adverse Events (AEs) |
49; 15 | — |
| SECONDARY Best Overall Tumor Response Per Investigator Review |
1; 0; 10; 7; 33; 6 | — |
| SECONDARY Number of Participants Who Discontinued Study Drug Due to an AE |
6; 3 | — |
| SECONDARY Best Overall Tumor Response Per Central Review |
0; 0; 10; 5; 31; 9 | — |
| SECONDARY Change From Baseline in Tumor Growth Rate |
0.49; 0.07; 0.41; 0.53; 0.19 | — |
Eligibility Criteria
Inclusion Criteria
- Older than 18 years of age, of any race, and gender;
- Diagnosis of histologically confirmed relapsed or recurrent colorectal carcinoma that has progressed on at least first-line therapy;
- Must have a computed tomography (CT) or magnetic resonance imaging (MRI) scan performed at some point during their immediate prior treatment or observation in order to determine tumor growth rate;
- Must have measurable disease on a CT or MRI study, performed during Screening;
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 7.5% in a participant with known diabetes mellitus;
- A recent myocardial infarction (within the past year); or a participant who at the time of Screening presents with unstable or uncontrolled angina, New York Heart Association Class III or IV congestive heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram abnormality;
- An active infection;
- Has clinically significant hepatitis at Screening, or is hepatitis C antibody positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV) seropositive.
Data sourced from ClinicalTrials.gov (NCT00551213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.